PMID: 6407077Jan 1, 1983Paper

Influence of cardiovascular drugs on platelet aggregation

Advances in Myocardiology
W FörsterU Zehl

Abstract

All vasodilatory drugs reported in this chapter possess an antiaggregatory effect on platelets, some of them with a synergistic effect on prostacyclin-induced inhibition of aggregation. Thus, the question seems valid whether the antiaggregatory effect represents one part of their antianginal and antihypertensive action. Some vasodilators stimulate the biosynthesis of prostacyclin and/or other vasodilating prostaglandins. This stimulation could be linked not only to the antiaggregatory but also to the vasodilating action. The influence on prostaglandin biosynthesis, however, is not obligatory for all vasodilators, as nitroglycerin proves. Trapidil inhibits the biosynthesis and the effect of thromboxane A2, as our own experiments and those by Ohnishi et al. (7) have shown. This effect could be favorable in patients with heart infarction. Lefer et al. (5) have demonstrated a fivefold increase in thromboxane release after experimental ligation of the coronary artery in the cat. Pinane thromboxane, a thromboxane antagonist, almost completely abolished all deleterious consequences of ischemia. Whether trapidil is also able to inhibit thromboxane biosynthesis and activity under clinical conditions of heart infarction will be the topic...Continue Reading

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.